XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.4
Unaudited Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Public Offering and Private Placement
Common Stock
Employees
Common Stock
Consultants
Common Stock
Director
Common Stock
Paid-in Capital
Employees
Paid-in Capital
Consultants
Paid-in Capital
Accumulated Deficit
Noncontrolling Interest
Employees
Consultants
Total
Balances at Dec. 31, 2022         $ 20     $ 103,592 $ (32,797) $ (676)     $ 70,139
Balances (in shares) at Dec. 31, 2022         19,624,860                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Compensation expense related to stock options and restricted stock               51         51
Shares issued to consultant in connection with stock grant             $ 6         $ 6  
Shares issued to consultant in connection with stock grant (in shares)     8,334                    
Net income (loss)                 (5,643) (295)     (5,938)
Balances at Mar. 31, 2023         $ 20     103,649 (38,440) (971)     64,258
Balances (in shares) at Mar. 31, 2023         19,633,194                
Balances at Dec. 31, 2022         $ 20     103,592 (32,797) (676)     70,139
Balances (in shares) at Dec. 31, 2022         19,624,860                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net income (loss)                         (15,042)
Balances at Sep. 30, 2023         $ 20     103,804 (47,052) (1,463)     55,309
Balances (in shares) at Sep. 30, 2023         19,800,053                
Balances at Mar. 31, 2023         $ 20     103,649 (38,440) (971)     64,258
Balances (in shares) at Mar. 31, 2023         19,633,194                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Compensation expense related to stock options and restricted stock               27         27
Shares issued to consultant in connection with stock grant             39         39  
Shares issued to consultant in connection with stock grant (in shares)     58,334                    
Shares issued on exercises of stock options, net of shares surrendered for cashless exercises (in shares)         9,128                
Net income (loss)                 (3,468) (233)     (3,701)
Balances at Jun. 30, 2023         $ 20     103,715 (41,908) (1,204)     60,623
Balances (in shares) at Jun. 30, 2023         19,700,656                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Compensation expense related to stock options and restricted stock               36         36
Contra-revenue related to warrants held by licensee               16         16
Shares issued in connection with stock grant           $ 10         $ 10    
Shares issued in connection with stock grant (in shares)   7,300                      
Shares issued in connection with restricted stock grants (in shares)       40,000                  
Shares issued on exercises of stock options, net of shares surrendered for cashless exercises               27         27
Shares issued on exercises of stock options, net of shares surrendered for cashless exercises (in shares)         52,097                
Net income (loss)                 (5,144) (259)     (5,403)
Balances at Sep. 30, 2023         $ 20     103,804 (47,052) (1,463)     55,309
Balances (in shares) at Sep. 30, 2023         19,800,053                
Balances at Jun. 30, 2023         $ 20     103,715 (41,908) (1,204)     60,623
Balances (in shares) at Jun. 30, 2023         19,700,656                
Balances at Sep. 30, 2024         $ 24     106,056 (69,161) (1,953)     $ 34,966
Balances (in shares) at Sep. 30, 2024         23,581,290                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Common stock, shares issued (in shares)                         19,795,053
Balances at Dec. 31, 2023         $ 20     103,861 (53,849) (1,861)     $ 48,171
Balances (in shares) at Dec. 31, 2023         19,795,053                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Compensation expense related to stock options and restricted stock               36         36
Contra-revenue related to warrants held by licensee               10         10
Shares issued in connection with stock grant             $ 98         $ 98  
Shares issued in connection with stock grant (in shares)     78,000                    
Shares issued in connection with public offering and private placement transactions, net of transaction costs         $ 3     1,899         1,902
Net income (loss)                 (6,294) (51)     (6,345)
Balances at Mar. 31, 2024         $ 23     105,904 (60,143) (1,912)     43,872
Balances (in shares) at Mar. 31, 2024         23,452,117                
Balances at Dec. 31, 2023         $ 20     103,861 (53,849) (1,861)     48,171
Balances (in shares) at Dec. 31, 2023         19,795,053                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Shares issued in connection with public offering and private placement transactions, net of transaction costs                         1,902
Net income (loss)                         (15,404)
Balances at Sep. 30, 2024         $ 24     106,056 (69,161) (1,953)     34,966
Balances (in shares) at Sep. 30, 2024         23,581,290                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Shares issued in connection with public offering and private placement transactions, net of transaction costs $ 1,900                        
Common stock, shares issued (in shares) 3,579,064                        
Common stock, shares issued (in shares)         3,579,064                
Balances at Mar. 31, 2024         $ 23     105,904 (60,143) (1,912)     43,872
Balances (in shares) at Mar. 31, 2024         23,452,117                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Compensation expense related to stock options and restricted stock               32         32
Contra-revenue related to warrants held by licensee               10         10
Shares issued in connection with stock grant (in shares)       40,000                  
Net income (loss)                 195 (34)     161
Balances at Jun. 30, 2024         $ 23     105,946 (59,948) (1,946)     44,075
Balances (in shares) at Jun. 30, 2024         23,492,117                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Compensation expense related to stock options and restricted stock               37         37
Contra-revenue related to warrants held by licensee               9         9
Shares issued in connection with stock grant           $ 10         $ 10    
Shares issued in connection with stock grant (in shares)   14,685                      
Share issued to executives for pro rata portion of base salaries, net of withholding taxes         $ 1     54         55
Shares issued to executives for pro rata portion of base salaries, net of withholding taxes (in shares)         74,488                
Net income (loss)                 (9,213) (7)     (9,220)
Balances at Sep. 30, 2024         $ 24     $ 106,056 $ (69,161) $ (1,953)     $ 34,966
Balances (in shares) at Sep. 30, 2024         23,581,290                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Common stock, shares issued (in shares)                         23,581,290